Search Within

Eytan Moshe Stein

Formats
  1. Meeting Abstract (217)
  2. Journal Article (104)
  3. Review (17)
  4. Research Letter (14)
  5. Editorial (5)
  6. Book Section (3)
  7. Guidelines (2)
  8. Correspondence (1)
  9. Miscellaneous (1)
Groups
  1. Adult Leukemia (364)
  2. Center for Hematologic Malignancies (364)
  3. Department of Medicine (364)
  4. Hematologic Malignancies, Division of (364)
  5. GSK Faculty (92)
  6. Executive Committee, Center for Hematologic Malignancies (87)

More Groups

People
  1. Martin Tallman (116)
  2. Ross Levine (75)
  3. Aaron Goldberg (41)
  4. Jan Bewersdorf (33)
  5. Andriy Derkach (31)
  6. Christopher Famulare (30)

More People

Years
  1. 2025 (14)
  2. 2024 (44)
  3. 2023 (49)
  4. 2022 (34)
  5. 2021 (31)
  6. 2020 (30)

More Years

Publications
  1. Blood (170)
  2. Journal of Clinical Oncology (23)
  3. Clinical Lymphoma, Myeloma and Leukemia (17)
  4. Haematologica (16)
  5. Blood Advances (14)
  6. Leukemia and Lymphoma (12)

More Publications

Publishers
  1. American Society of Hematology (185)
  2. Elsevier Inc. (30)
  3. American Society of Clinical Oncology (27)
  4. Ferrata Storti Foundation (16)
  5. Nature Publishing Group (15)
  6. Taylor & Francis Group (12)

More Publishers

Results (364)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The prognostic and predictive value of RUNX1 mutations in newly diagnosed acute myeloid leukemia - An international multicenter cohort study
    Meeting Abstract

    Bystrom, R. P.; Bewersdorf, J. P.; Liu, Y.; Schaefer, E. J.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Garciaz, S.; Aguirre, L. E.; DeAngelo, D. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Updated results and longer follow-up from the AUGMENT-101 phase 2 study of revumenib in all patients with relapsed or refractory (R/R) KMT2Ar acute leukemia
    Meeting Abstract

    Aldoss, I.; Issa, G. C.; Blachly, J. S.; Thirman, M. J.; Mannis, G. N.; Arellano, M. L.; DiPersio, J. F.; Traer, E.; Zwaan, C. M.; Shukla, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • River-52: A multicenter, open-label clinical trial of RVU120 in patients with relapsed or refractory high-risk myelodysplastic syndrome or acute myeloid leukemia
    Meeting Abstract

    Papayannidis, C.; Madry, K.; Centkowski, P.; Prejzner, W.; Butrym, A.; Chraniuk, D.; Saba, C.; Angelosanto, N.; Curley, R.; Nogai, H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients with chromosome 5 and 7 abnormalities
    Meeting Abstract

    Boussi, L.; Bewersdorf, J. P.; Liu, Y.; Shallis, R. M.; Aguirre, L. E.; Zucenka, A.; Garciaz, S.; Bystrom, R. P.; DeAngelo, D. J.; Stone, R. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Outcomes and survival in newly diagnosed, older, acute myeloid leukemia patients from the beat AML master trial in the venetoclax/azacitidine age
    Meeting Abstract

    Borate, U.; Huang, Y.; Li Welkie, R.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Madanat, Y. F.; Patel, P. A.; Collins, R. H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with lower-intensity therapy
    Meeting Abstract

    Hoff, F. W.; Huang, Y.; Li Welkie, R.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Patel, P. A.; Collins, R. H.; Baer, M. R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Comparative analysis of outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients harboring very-high risk cytogenetics
    Meeting Abstract

    Aguirre, L. E.; Bewersdorf, J. P.; Liu, Y.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Garciaz, S.; Bystrom, R. P.; Deangelo, D. J.; Stone, R. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with relapsed or refractory, splicing factor-mutant myeloid malignancies
    Meeting Abstract

    Bewersdorf, J. P.; Mi, X.; Lu, B.; Kuykendall, A. T.; Sallman, D.; Patel, M.; Stevens, D. A.; Philipovskiy, A.; Sutamtewagul, G.; Masarova, L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Patients with AML and an IDH2-R172 mutation exhibit a unique response to intensive induction chemotherapy, suggesting futility of mid-cycle bone marrow biopsy and caution when considering re-induction
    Meeting Abstract

    Yisraeli Salman, M.; Terry, A. R.; Derkach, A.; Nemirovsky, D.; Chin, K. K.; Valtis, Y. K.; Boussi, L.; Spivey, T.; Xiao, W.; Famulare, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Single-cell spatial transcriptomics identifies lymphoid aggregates with location-specific alterations of adaptive immune cells in human MDS bone marrow
    Meeting Abstract

    Stanley, R.; Zhang, B.; Argyropoulos, K.; Gipson, B.; Weis, K.; Lewis, A. M.; Katsamakis, Z.; Zhao, K.; Snopkowski, C.; Zatzman, M.; more...
    Blood (2024)

    Fulltext@MSK | Save